 |
|
|
| |
Pharmacokinetic Interactions Between the HCV NS5A Inhibitor MK-8742 and
Tenofovir (TDF), Raltegravir (RAL), and Efavirenz (EFV)
|
| |
| |
CROI: On-treatment Viral Response to MK-5172/MK-8742 ± RBV for 12 Weeks in HCV/HIV Co-infected Patients: The C-WORTHY Study - (03/06/14)
HCV Coverage at CROI - (03/10/14)
Reported by Jules Levin
CROI 2014 March 3-6
Boston, MA
WW Yeh,1 W Marshall,1 J Ma,1 E Mangin,1 X Huang,1 Y Zhu,1 S Langley,1 P Jumes,1 S Youngberg,2 JR Butterton1
1Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA; 2Celerion, Lincoln, NE, USA
|
| |
|
|
|
|
|
